Information Provided By: 
Fly News Breaks for June 4, 2015
RVNC
Jun 4, 2015 | 06:59 EDT
William Blair raised its price target for Revance Therapeutics to $45 citing an increase in probability of success for RT001 to 50% from 25% following yesterday's announcement as well as the probability of success of RT002 to 50% from 40% as a result of the enrollment completion of Belmont and study design. The firm keeps an Outperform rating on the name.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
